The estimated Net Worth of Mark C Wiggins is at least $6.06 Million dollars as of 29 December 2020. Mr. Wiggins owns over 1,000 units of TRACON Pharmaceuticals Inc stock worth over $945 and over the last 20 years he sold TCON stock worth over $5,455,311. In addition, he makes $603,016 as Chief Business Officer at TRACON Pharmaceuticals Inc.
Mark has made over 34 trades of the TRACON Pharmaceuticals Inc stock since 2004, according to the Form 4 filled with the SEC. Most recently he bought 1,000 units of TCON stock worth $10,570 on 29 December 2020.
The largest trade he's ever made was exercising 89,645 units of TRACON Pharmaceuticals Inc stock on 15 October 2007 worth over $5,895,952. On average, Mark trades about 8,853 units every 102 days since 2004. As of 29 December 2020 he still owns at least 13,700 units of TRACON Pharmaceuticals Inc stock.
You can see the complete history of Mr. Wiggins stock trades at the bottom of the page.
Mark C. Wiggins serves as Chief Business Officer of the Company. Prior to joining us, Mr. Wiggins served as Chief Executive Officer at selectION Therapeutics, Inc., from 2017 to 2018, Senior Vice President of Corporate and Business Development at Elcelyx Therapeutics from 2012 to 2015, and Chief Business Officer at Mpex Pharmaceuticals from 2009 to 2011. Prior to this, he served as Executive Vice President of Corporate and Business Development at Biogen Idec, Inc. from 2003 to 2009 and Vice President of Marketing and Business Development at IDEC Pharmaceuticals from 1998 to 2003. Mr. Wiggins also previously served as Head of U.S. Business Development at Schering-Plough (now Merck), in addition to roles at Pfizer and Johnson & Johnson. Mr. Wiggins currently serves on the board of directors of Zogenix and SelectION. He received a B.S. in finance from Syracuse University and an M.B.A. from the University of Arizona.
As the Chief Business Officer of TRACON Pharmaceuticals Inc, the total compensation of Mark Wiggins at TRACON Pharmaceuticals Inc is $603,016. There are 2 executives at TRACON Pharmaceuticals Inc getting paid more, with Charles Theuer having the highest compensation of $1,085,320.
Mark Wiggins is 64, he's been the Chief Business Officer of TRACON Pharmaceuticals Inc since 2018. There are 4 older and 10 younger executives at TRACON Pharmaceuticals Inc. The oldest executive at TRACON Pharmaceuticals Inc is William LaRue, 69, who is the Independent Director.
Mark's mailing address filed with the SEC is C/O ZOGENIX, INC., 5858 HORTON STREET, #455, EMERYVILLE, CA, 94608.
Over the last 10 years, insiders at TRACON Pharmaceuticals Inc have traded over $6,301,907 worth of TRACON Pharmaceuticals Inc stock and bought 27,278,043 units worth $151,387,355 . The most active insiders traders include Forest Baskett, Scott D Sandell und Anthony A. Jr. Florence. On average, TRACON Pharmaceuticals Inc executives and independent directors trade stock every 22 days with the average trade being worth of $15,278. The most recent stock trade was executed by Management Inc. Opaleye on 10 November 2023, trading 4,764,008 units of TCON stock currently worth $1,381,562.
tracon pharmaceuticals, inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (amd). its lead clinical stage products include envafolimab (kn035), an investigational pd-l1 single-domain antibody for the treatment of soft tissue sarcoma. the company's clinical stage products also include de-122, which is in randomized phase iia study for the treatment of wet amd; trc102, which is a small molecule that is in phase ii clinical trial for the treatment of mesothelioma, phase i clinical trial to treat solid tumors, phase i/ii to treat solid tumors and lymphomas, and phase i trial to treat lung cancer; trc253, a small molecule, which is in a phase ii clinical trial for the treatment of metastatic castration-resistant prostate cancer; and tj004309, a cd73 antibody that is in phase i clinical development for the treatment of solid tumors. it has collaboration and license agreements w
TRACON Pharmaceuticals Inc executives and other stock owners filed with the SEC include: